Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US

Por Bharmal, Murtuza, Kearney, Mairead, Zheng, Ying, Phatak, Hemant
Publicado no Clinicoecon Outcomes Res (2019)

Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials

Por Bharmal Murtuza, Bhanegaonkar Abhijeet, Canafax Daniel M, Calloway Michael
Publicado em 2011-04-01

Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials

Por Canafax, Daniel M, Bhanegaonkar, Abhijeet, Bharmal, Murtuza, Calloway, Michael
Publicado em 2011

Trends in CNS Prescribing Following the Economic Slowdown

Por Cascade, Elisa, Kalali, Amir H., Kwentus, Joseph A., Bharmal, Murtuza
Publicado em 2009

Update on the psychometric properties and minimal important difference (MID) thresholds of the FACT-M questionnaire for use in treatment-naïve and previously treated patients with...

Por Bharmal, Murtuza, Nolte, Sandra, Henry-Szatkowski, Mickaël, Hennessy, Meliessa, Schlichting, Michael
Publicado no Health Qual Life Outcomes (2020)

Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection

Por Bullement, Ash, Willis, Anna, Amin, Amerah, Schlichting, Michael, Hatswell, Anthony James, Bharmal, Murtuza
Publicado no BMC Med Res Methodol (2020)

How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical t...

Por Bharmal, Murtuza, Guillemin, Isabelle, Marrel, Alexia, Arnould, Benoit, Lambert, Jérémy, Hennessy, Meliessa, Fofana, Fatoumata
Publicado no Orphanet J Rare Dis (2018)

Living with Merkel Cell Carcinoma (MCC): Development of a Conceptual Model of MCC Based on Patient Experiences

Por Kaufman, Howard L., Dias Barbosa, Carla, Guillemin, Isabelle, Lambert, Jérémy, Mahnke, Lisa, Bharmal, Murtuza
Publicado no Patient (2018)

Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma

Por Nghiem, Paul, Kaufman, Howard L, Bharmal, Murtuza, Mahnke, Lisa, Phatak, Hemant, Becker, Jürgen C
Publicado no Future Oncol (2017)

Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab

Por Lanitis, Tereza, Proskorovsky, Irina, Ambavane, Apoorva, Hunger, Matthias, Zheng, Ying, Bharmal, Murtuza, Phatak, Hemant
Publicado no Adv Ther (2019)

Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives

Por Kongnakorn, Thitima, Bharmal, Murtuza, Kearney, Mairead, Phatak, Hemant, Benedict, Agnes, Bhanegaonkar, Abhijeet, Galsky, Matthew
Publicado no Clinicoecon Outcomes Res (2019)

Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications

Por Bharmal, Murtuza, Payne, Krista, Atkinson, Mark J, Desrosiers, Marie-Pierre, Morisky, Donald E, Gemmen, Eric
Publicado em 2009

Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma

Por Bharmal, Murtuza, Fofana, Fatoumata, Barbosa, Carla Dias, Williams, Paul, Mahnke, Lisa, Marrel, Alexia, Schlichting, Michael
Publicado no Health Qual Life Outcomes (2017)

Correction to: Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma

Por Bharmal, Murtuza, Fofana, Fatoumata, Barbosa, Carla Dias, Williams, Paul, Mahnke, Lisa, Marrel, Alexia, Schlichting, Michael
Publicado no Health Qual Life Outcomes (2019)

Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma

Por Bullement, Ash, Nathan, Paul, Willis, Anna, Amin, Amerah, Lilley, Cameron, Stapelkamp, Ceilidh, Hatswell, Anthony, Pescott, Chris, Bharmal, Murtuza
Publicado no Pharmacoecon Open (2019)

Treatment Sequencing Patterns in Patients with Metastatic Urothelial Cancer Treated in the Community Practice Setting in the United States: SPEAR-Bladder (Study informing treatment...

Por Doshi, Gurjyot K, Bhanegaonkar, Abhijeet, Kearney, Mairead, Bharmal, Murtuza, Cislo, Paul, Kim, Ruth, Boyd, Marley, Aguilar, Kathleen M, Phatak, Hemant
Publicado no Clinicoecon Outcomes Res (2020)

Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinica...

Por Lambert, Jérémy, Marrel, Alexia, D’Angelo, Sandra P., Burgess, Melissa A., Chmielowski, Bartosz, Fazio, Nicola, Gambichler, Thilo, Grob, Jean-Jacques, Lebbé, Céleste, Robert, Caroline, Russell, Jeffrey, Güzel, Gülseren, Bharmal, Murtuza
Publicado no Patient (2020)

Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe

Por Becker, Jürgen C., Lorenz, Eva, Ugurel, Selma, Eigentler, Thomas K., Kiecker, Felix, Pföhler, Claudia, Kellner, Ivonne, Meier, Friedegund, Kähler, Katharina, Mohr, Peter, Berking, Carola, Haas, Gabriele, Helwig, Christoph, Oksen, Dina, Schadendorf, Dirk, Mahnke, Lisa, Bharmal, Murtuza
Publicado no Oncotarget (2017)

Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma

Por D’Angelo, Sandra P., Hunger, Matthias, Brohl, Andrew S., Nghiem, Paul, Bhatia, Shailender, Hamid, Omid, Mehnert, Janice M., Terheyden, Patrick, Shih, Kent C., Brownell, Isaac, Lebbé, Céleste, Lewis, Karl D., Linette, Gerald P., Milella, Michele, Schlichting, Michael, Hennessy, Meliessa H., Bharmal, Murtuza
Publicado no Cancer Immunol Immunother (2019)